Merck (MRK) EVP Richard DeLuca Sells 45,320 Shares

What Happened Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold a total of 45,320 Merck shares in multiple open-market transactions between Aug 10 and Aug 12, 2026, generating roughly $5.94 million in gross proceeds. The trades break down as: 20,784 shares at a weighted avg $130.43 ($2,710,951); 7,410 shares at $131.33 ($973,165); 5,427 shares at $132.35 ($718,261); 11,099 shares at $131.61 ($1,460,770); and 600 shares at $132.04 ($79,222). These are sales (transaction code S), which are commonly routine (e.g., diversification or tax-related) rather than a buy signal.

Key Details

• Dates and prices (weighted averages):
  • Aug 10, 2026 — 20,784 sh @ $130.43 (total ~$2.71M). Range: $130.0000–$130.9500 (F1).
  • Aug 11, 2026 — 7,410 sh @ $131.33 (total ~$973k). Range: $131.0000–$131.9800 (F2).
  • Aug 11, 2026 — 5,427 sh @ $132.35 (total ~$718k). Range: $132.0000–$132.6514 (F3).
  • Aug 12, 2026 — 11,099 sh @ $131.61 (total ~$1.46M). Range: $131.0000–$131.9950 (F4).
  • Aug 12, 2026 — 600 sh @ $132.04 (total ~$79k). Range: $132.0000–$132.0700 (F5).
• Total shares sold: 45,320; total gross proceeds ≈ $5.94 million.
• Shares owned after the transactions: not specified in the provided summary of the filing.
• Notable footnotes: reported prices are weighted averages; each footnote provides the per-transaction price ranges and the filer offers to supply per-price details on request.
• Timeliness: Filing date 2026-08-12 for transactions Aug 10–12; the filing shows no indication of being late.

Context This was a straight sale of shares (S). Sales by executives can reflect routine portfolio management, tax obligations, or other personal reasons and should not be read alone as a company valuation signal. No 10b5-1 plan, option exercises, awards, or gifts were indicated in the provided filing details.